Semaglutide
Semaglutide (GLP-1 Receptor Agonist)
The most widely used and well-studied GLP-1 weight loss medication, producing around 15% body weight reduction with once-weekly dosing.
Semaglutide is a medication that mimics a natural gut hormone called GLP-1, which your body releases after eating to signal fullness. It is FDA approved and available under two brand names: Wegovy for weight management and Ozempic for type 2 diabetes. Unlike newer compounds still being tested in clinical trials, semaglutide has been on the market since 2017 and has extensive real-world use backing its safety and effectiveness. It is one of the most thoroughly studied weight loss medications ever developed.
The way semaglutide works is straightforward: it tells your brain you are full, slows down how fast food leaves your stomach, and improves how your body handles blood sugar. Most people find that their appetite naturally decreases, cravings become less intense, and they feel satisfied with smaller meals. The medication is given as a simple injection once per week, and its long-lasting design means you get consistent effects throughout the entire week without peaks and valleys.
Semaglutide has become a household name in the weight loss world for good reason. In the largest clinical trials, people lost an average of about 15% of their body weight, which for a 250-pound person would be roughly 37 pounds. Beyond weight loss, the medication has also been shown to protect against heart attacks and strokes, making it valuable for overall health and not just the number on the scale.
How It Works
Think of your appetite as being controlled by a thermostat in your brain. When that thermostat is set too high, you feel hungry more often and crave larger portions. Semaglutide works by turning that thermostat down. It activates GLP-1 receptors in the hypothalamus and brainstem, which are the parts of your brain responsible for hunger signals. When these receptors are switched on, your brain gets a strong and sustained message that you have had enough to eat, making it easier to eat less without feeling deprived or constantly fighting willpower.
Beyond the brain, semaglutide also slows down how quickly food moves through your stomach. Imagine your stomach as a container that normally empties at a steady pace after a meal. Semaglutide puts the brakes on that process, keeping food in your stomach longer so you feel full and satisfied for hours after eating. This is why many users find they naturally skip snacks and eat smaller portions without having to consciously restrict themselves. The medication also reduces the reward value of food, meaning high-calorie foods like pizza or sweets become less appealing on a neurological level.
On the blood sugar side, semaglutide helps your pancreas release insulin more effectively when your blood sugar rises after a meal, and it also reduces glucagon, a hormone that raises blood sugar. This two-pronged effect improves blood sugar control without causing dangerous drops in blood sugar for most people. The medication has a half-life of about 7 days, which is why a single weekly injection keeps everything working smoothly around the clock.
Potential Benefits
Significant Weight Loss
Clinical trials showed participants lost an average of 14.9% of their body weight over 68 weeks, with half of all users losing 15% or more. This level of weight loss was previously only achievable through bariatric surgery.
Blood Sugar Control
Even in people without diabetes, semaglutide improves fasting glucose and insulin sensitivity. For those with type 2 diabetes, it produces meaningful reductions in HbA1c, helping bring blood sugar levels closer to normal.
Cardiovascular Protection
The SELECT trial demonstrated a 20% reduction in the risk of major cardiovascular events including heart attack, stroke, and cardiovascular death in people with obesity and established heart disease.
Sustained and Steady Results
Unlike crash diets that produce rapid weight loss followed by rebound, semaglutide produces gradual, steady weight loss over months. Most users continue losing weight through the full treatment period and into maintenance.
Reduced Food Cravings
Research suggests GLP-1 agonists reduce the reward value of food at a neurological level, making high-calorie foods less appealing and reducing the constant mental chatter about food that many people with obesity experience.
What the Research Shows
The STEP-1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity and gave them either semaglutide 2.4 mg weekly or a placebo for 68 weeks. The semaglutide group lost an average of 14.9% of their body weight compared to just 2.4% in the placebo group. Even more impressive, 86% of semaglutide users lost at least 5% of their body weight, 69% lost at least 10%, and half lost 15% or more. The STEP-3 trial combined semaglutide with intensive behavioral therapy and saw participants lose an average of 16%, showing that lifestyle changes amplify the medication's effects.
In 2023, the SELECT trial made headlines by demonstrating that semaglutide does more than just help people lose weight. This massive cardiovascular outcomes trial enrolled over 17,000 participants with obesity and established heart disease. Semaglutide reduced the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, by 20% compared to placebo. This was a landmark finding because it proved the medication provides direct heart protection beyond what weight loss alone would explain.
When compared to other weight loss medications, semaglutide produces roughly 15% average weight loss at its maximum dose of 2.4 mg weekly. Tirzepatide, a newer dual-receptor drug, produces about 21% weight loss. Retatrutide, which is still investigational, has shown around 24% weight loss in Phase 2 trials. However, semaglutide has the longest track record and the most extensive safety data of any medication in this class, which many people and doctors find reassuring.
What to Know
Nausea is the most frequently reported side effect, affecting up to 44% of users during the initial weeks. Vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue are also common during the dose increase phase. These effects are dose-dependent and typically improve significantly after the first 4 to 8 weeks as the body adapts.
Less common effects include acid reflux, heartburn, bloating, gas, dizziness, and mild injection site reactions. These generally do not require stopping the medication and tend to resolve on their own.
People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use semaglutide. It should also be avoided during pregnancy and breastfeeding. Those with a history of pancreatitis, diabetic retinopathy, kidney disease, gallbladder disease, or depression should use it only with close medical supervision.
Seek immediate medical attention for persistent vomiting that does not resolve, severe abdominal pain which could indicate pancreatitis, signs of allergic reaction such as rash, swelling, or difficulty breathing, signs of thyroid tumors like a neck mass or persistent hoarseness, or severe hypoglycemia if taking semaglutide alongside insulin or sulfonylureas.
Research References
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al. · New England Journal of Medicine · 2021
The landmark STEP-1 trial with 1,961 adults showed that semaglutide 2.4 mg weekly produced 14.9% average weight loss over 68 weeks, with 86% of participants losing at least 5% of body weight and half losing 15% or more.
View StudySemaglutide 2.4 mg once a week in adults with overweight or obesity (STEP-3)
Davies M, Faerch L, Jeppesen OK, et al. · The Lancet · 2021
Combined semaglutide with intensive behavioral therapy and demonstrated 16% average body weight loss, showing that lifestyle changes amplify the medication's effects beyond what either approach achieves alone.
View StudySemaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial)
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · New England Journal of Medicine · 2023
Cardiovascular outcomes trial with over 17,000 participants demonstrating that semaglutide reduced major adverse cardiovascular events by 20% compared to placebo in people with obesity and established heart disease.
View Study